Study guide
9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines
PTCB Technician Product Verification TPV
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Tech-Check-Tech Verification Fundamentals
1.1 About the PTCB TPV Certificate Exam 1.2 Tech-Check-Tech (TCT) Scope, Regulations, and Quality Assurance 1.3 Systematic Verification Protocol & Visual Inspection Steps
2 Chapter 2: Drug Name Verification & Brand/Generic Identification
2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence 2.2 Salt Forms and Active Ingredient Verification 2.3 Manufacturer-Specific Identification, Visual Cues, and Color Codes
3 Chapter 3: Auxiliary Labels, REMS & Controlled Substances
3.1 Auxiliary Warning Labels and Mandatory Patient Counseling Triggers 3.2 REMS Programs and Restricted Distribution Medications 3.3 Controlled Substance Scheduling, Refill Restrictions, and C-II Exact Counts
4 Chapter 4: Dosage Forms, Release Mechanisms & Administration Routes
4.1 Modified-Release Formulations (ER, XL, SR, DR, CR) and "Do Not Crush" Rules 4.2 Route of Administration Verification: Ophthalmic vs Otic, Oral vs Topical vs Transdermal 4.3 Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs Suspensions
5 Chapter 5: Strength Verification & Pharmaceutical Calculations
5.1 Unit Conversions (mcg, mg, g) and Preventing Leading/Trailing Zero Errors 5.2 Percentage Strengths, Ratio Strengths, and Liquid Concentrations (mg/mL) 5.3 Electrolyte Equivalents (mEq vs mg) and Combination Product Strength Verification
6 Chapter 6: High-Alert Medications & Safety Protocols
6.1 ISMP High-Alert Medications and Independent Double-Check Protocols 6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math 6.3 Concentrated Electrolytes, Opioids, Neuromuscular Blockers, and Oral Methotrexate
7 Chapter 7: Look-Alike / Sound-Alike (LASA) Medications
7.1 FDA and ISMP Tall-Man Lettering Principles 7.2 High-Risk Community/Ambulatory LASA Pairs 7.3 High-Risk Institutional/Hospital LASA Pairs & Packaging Traps
8 Chapter 8: Packaging, Expiration, Storage & Special Handling
8.1 Expiration Date Interpretation and Multi-Dose Vial Beyond-Use Dating (BUD) 8.2 Packaging Integrity, Moisture/Light Sensitivity, and FDA Recall Classes 8.3 Temperature Storage Ranges and Vaccine Cold Chain Integrity 8.4 USP <800> Hazardous Drug Identification and Handling Precautions
9 Chapter 9: NDC Conversion, Repackaging & Final Dispensing Checks
9.1 NDC 10-Digit to 11-Digit Conversion (5-4-2 Standardization) 9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines 9.3 Days Supply Calculations, Package Size Verification, and Final Label Matching
9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines
Key Takeaways Explain This Topic AI
Unit-dose packaging encloses a single dose of medication ready for administration, minimizing bedside measurement errors, enhancing inventory tracking, and enabling the return of unadministered sealed doses.
Under USP <795> and FDA repackaging guidelines, the Beyond-Use Date (BUD) for non-sterile solid oral unit-dose repackaged drugs shall not exceed EITHER 6 months from the date of repackaging OR 25% of the remaining manufacturer expiration date, WHICHEVER IS SHORTER.
The assigned BUD can never exceed the manufacturer's original expiration date under any circumstances.
Every unit-dose package must display mandatory label elements: generic/brand name, strength, dosage form, repackager lot number, BUD, manufacturer name, special storage requirements, and auxiliary labels.
A comprehensive Repackaging Control Log must be maintained for every batch, documenting manufacturer lot, original expiration, assigned internal lot, assigned BUD, quantity packaged, packaging materials, and technician/pharmacist verification signatures.
Last updated: August 2026
Unit-Dose Repackaging Standards and USP <795> BUD Guidelines
Core Verification Rule: Unit-dose repackaging transforms bulk commercial stock into individually sealed, barcoded single doses ready for patient administration. The verifying technician must confirm that every unit-dose blister or cup contains all required regulatory label elements, an accurate internal lot number, and an assigned Beyond-Use Date (BUD) calculated strictly in compliance with the USP <795> 6-Month or 25% Rule.
In acute care hospitals, health systems, and long-term care (LTC) facilities, the unit-dose drug distribution system represents the clinical gold standard for patient safety. Rather than dispensing multi-dose bulk bottles to patient care areas, the pharmacy prepares and distributes medications in individual unit-of-use packages containing the exact dose ordered for a single administration time.
1. Principles and Modalities of Unit-Dose Packaging
Unit-dose packaging provides multiple clinical and operational safeguards:
Error Reduction: Eliminates the need for nursing staff to measure liquids, count tablets, or manipulate dosage forms at the bedside.
Contamination Prevention: Protects individual dosage units from atmospheric moisture, light, air, and microbial contamination until the moment of consumption.
Inventory & Waste Control: Unopened, undamaged unit-dose packages returned from nursing units can be safely restocked into pharmacy inventory (unlike opened bulk patient vials).
Bedside Barcode Verification (BCMA): Enables nurses to scan both the patient's ID wristband and the unit-dose barcode to achieve five-rights verification at the bedside.
Common Packaging Formats
Packaging Modality Clinical Setting Typical Dosage Forms Packaging Materials / Equipment
Blister Cards (Unit-Dose Blisters) Inpatient Hospitals, LTC Oral solid tablets, capsules PVC / Aclar thermoform blisters heat-sealed with foil backing (USP Class A or B barrier)
Unit-Dose Liquid Cups Inpatient Hospitals Oral solutions, suspensions, elixirs Polyethylene / polypropylene cups sealed with peelable aluminum foil lid
Strip Packaging (Pouches) Centralized Fill, LTC Solid oral solids, multi-med compliance Automated high-speed packagers (Pacmed, Parata) producing continuous cellophane/poly pouches
Oral Syringes (Unit-Dose) Pediatric & Adult Inpatient Oral liquids, critical titrations Amber or clear oral dispensers with tamper-evident tip caps (never accepting IV luer needles)
Bingo Cards / Multi-Dose Cards Skilled Nursing Facilities 30-day or 31-day blister cards Multi-cavity blister sheets with cold-seal or heat-seal foil backing
2. USP <795> and FDA Beyond-Use Date (BUD) Guidelines
A fundamental concept tested on the TPV exam is the regulatory and scientific distinction between a manufacturer's Expiration Date and a pharmacy's Beyond-Use Date (BUD) :
Manufacturer Expiration Date: Determined by the pharmaceutical manufacturer through extensive stability, sterility, and degradation testing in the original commercial container closure. It represents the date until which the drug is guaranteed to maintain full potency, chemical purity, and physical stability.
Beyond-Use Date (BUD): Assigned by the pharmacy or repackager when a drug product is removed from its original manufacturer packaging and transferred into a new container closure (e.g., unit-dose blister, oral syringe, or prescription vial). It reflects the shortened timeframe during which the repackaged preparation can be safely administered.
The "6-Month or 25% Rule" for Non-Sterile Solid Oral Repackaging
According to USP General Chapter <795> ( Pharmaceutical Compounding — Nonsterile Preparations ) and FDA Repackaging Guidance for Solid Oral Dosage Forms , when non-sterile solid oral dosage forms (tablets, capsules) are repackaged into unit-dose containers using USP Class A or Class B packaging materials, the assigned BUD shall not exceed:
Important
The USP <795> Non-Sterile Repackaging BUD Rule: The assigned Beyond-Use Date (BUD) shall be the SHORTER of:
6 months (180 days) from the date of repackaging, OR
25% of the remaining time between the repackaging date and the manufacturer's original expiration date.
Condition: In no circumstance may the assigned BUD exceed the manufacturer's original expiration date. BUD = Date of Repackaging + MIN [ 6 Months, (0.25 × Remaining Time to Mfg Expiration) ]
3. Step-by-Step Mathematical BUD Calculations
To determine the exact BUD, technicians must follow a systematic 4-step calculation sequence:
Calculate Remaining Shelf Life: Count the total months (or days) from the date of repackaging to the manufacturer's expiration date.
Calculate 25% of Remaining Time: Multiply the remaining shelf life by 0.25 (or divide by 4).
Compare Against 6-Month Threshold: Compare the 25% calculated value against 6 months.
Assign the Shorter Period: Add the shorter duration to the repackaging date to establish the final BUD.
- Calculation Scenarios
- Scenario 1: Manufacturer Expiration is 12 Months Away
- Repackaging Date: January 1, 2026
- Manufacturer Expiration: January 1, 2027 (12 months remaining)
- Step 1: Remaining shelf life = 12 months 12\text{ months} 12 months
- Step 2: 25 % × 12 months = 3 months 25\% \times 12\text{ months} = 3\text{ months} 25% × 12 months = 3 months
Step 3: Compare 3 months vs. 6 months → \rightarrow → 3 months < 6 months 3\text{ months} < 6\text{ months} 3 months < 6 months
- Step 4: Assigned BUD = January 1, 2026 + 3 months = April 1, 2026
- Scenario 2: Manufacturer Expiration is 36 Months Away
- Repackaging Date: March 1, 2026
- Manufacturer Expiration: March 1, 2029 (36 months remaining)
- Step 1: Remaining shelf life = 36 months 36\text{ months} 36 months
- Step 2: 25 % × 36 months = 9 months 25\% \times 36\text{ months} = 9\text{ months} 25% × 36 months = 9 months
Step 3: Compare 9 months vs. 6 months → \rightarrow → 6 months < 9 months 6\text{ months} < 9\text{ months} 6 months < 9 months
- Step 4: Assigned BUD = March 1, 2026 + 6 months = September 1, 2026 (Capped at 6 months!)
- Scenario 3: Manufacturer Expiration is 4 Months Away
- Repackaging Date: May 1, 2026
- Manufacturer Expiration: September 1, 2026 (4 months remaining)
- Step 1: Remaining shelf life = 4 months 4\text{ months} 4 months
- Step 2: 25 % × 4 months = 1 month 25\% \times 4\text{ months} = 1\text{ month} 25% × 4 months = 1 month
Step 3: Compare 1 month vs. 6 months → \rightarrow → 1 month < 6 months 1\text{ month} < 6\text{ months} 1 month < 6 months
- Step 4: Assigned BUD = May 1, 2026 + 1 month = June 1, 2026
- Scenario 4: Manufacturer Expiration is 24 Months Away
- Repackaging Date: July 15, 2026
- Manufacturer Expiration: July 15, 2028 (24 months remaining)
- Step 1: Remaining shelf life = 24 months 24\text{ months} 24 months
- Step 2: 25 % × 24 months = 6 months 25\% \times 24\text{ months} = 6\text{ months} 25% × 24 months = 6 months
- Step 3: Compare 6 months vs. 6 months → \rightarrow → Equal (6 months)
- Step 4: Assigned BUD = July 15, 2026 + 6 months = January 15, 2027
- 4. Required Unit-Dose Label Elements
Because unit-dose packages are small, every square millimeter of label space is regulated. The FDA, USP, and State Boards of Pharmacy mandate that every individual unit-dose package contain specific minimum data points: ┌────────────────────────────────────────────────────────┐
- │ METOPROLOL TARTRATE [Rx Only] │
- │ 50 mg Film-Coated Tablet │
- │ Mfg: Teva Pharmaceuticals │
- │ Repackaged Lot: PKG-2026-0829 │
- │ BUD: 02/28/2027 Store at 20°-25°C (Excursions) │
- │ ║▌║█║▌║▌║███║▌║ NDC: 00093-0123-01 │
- └────────────────────────────────────────────────────────┘
- Mandatory Unit-Dose Labeling Checklist
Generic Name: Non-proprietary generic drug name (prominently displayed; e.g., Metoprolol Tartrate ).
Brand Name: Proprietary trade name if applicable (e.g., Lopressor ), especially if brand-specific.
Strength and Concentration: Numerical strength and unit of measure (e.g., 50 mg , 250 mg/5 mL ).
Dosage Form: Specific physical form (e.g., Tablet , Capsule , Oral Solution , Extended-Release Tablet ).
Assigned Beyond-Use Date (BUD): Clear date beyond which the dose cannot be administered.
Pharmacy / Repackager Lot Number: Internal control lot number linking the package back to the master repackaging log.
Manufacturer Name: Name of the original commercial manufacturer (or repackaging facility name).
Special Storage Conditions: Specific temperature or environmental warnings (e.g., Refrigerate 2°–8°C , Protect from Light , Do Not Freeze ).
Auxiliary Warning Labels: Required cautionary statements (e.g., Chemotherapy / Hazardous Drug , Do Not Crush , Shake Well Before Using ).
Machine-Readable Barcode: Linear (Code 128) or 2D Data Matrix barcode encoding NDC, internal lot, and BUD for bedside scanning.
5. Repackaging Control Logs & Quality Audit Trails
Maintaining a meticulous Repackaging Control Log (Master Batch Record) is legally required. In the event of a commercial manufacturer recall or packaging integrity failure, the pharmacy must be able to instantly trace every repackaged unit back to its original source.
Log Sheet Field Operational Requirement & Regulatory Purpose
Repackaging Date Date the batch was packaged; establishes baseline for BUD calculation.
Drug Generic & Brand Name Complete chemical name, salt form, and brand equivalent.
Strength & Dosage Form Exact potency and physical formulation.
Commercial Manufacturer Name of the original drug manufacturer.
Manufacturer Original Lot # Source lot number printed on the bulk manufacturer stock bottle.
Manufacturer Expiration Date Original expiration date from bulk container.
Assigned Internal Lot / Batch # Unique serial control number assigned by the pharmacy (e.g., LOT-2026-0829-01 ).
Assigned Beyond-Use Date (BUD) Calculated BUD accompanied by calculation rationale.
Quantity Repackaged Total count of unit doses produced in the batch (e.g., 500 unit-dose tablets).
Packaging Material & Equipment Class of blister foil, cup type, seal temperature, and machine ID used.
Technician Signature / Initials Signature of the packaging technician who prepared the batch.
Pharmacist / TPV Verification Sign-off Signature of the verifying professional who inspected the batch and approved release.
Caution
Recall Traceability Protocol: If the FDA announces a Class I recall for a specific manufacturer lot number, the pharmacy must query its Repackaging Control Logs to identify every internal lot number linked to that bulk lot. Verifying technicians must pull all matching unit doses from automated dispensing cabinets, floor stock, and cart fills immediately.